Osteoarthritis (OA) is driven by biomechanical and biochemical inflammatory processes, including CD4+ T cell infiltration and activation. However, the role of CD4+ T cell subsets interacting with neighboring cells shaping the local inflammatory milieu have remained largely unexplored. This study aimed to investigate in vitro whether interaction of chondrocyte and CD4+ T cells modulate cytokine and metalloproteinase production in OA, and to determine if this modulation differ depending on CD4+ T cell subsets. Nineteen patients with knee OA undergoing knee replacement were enrolled. From peripheral blood CD4+ T cells were isolated and differentiated into subsets (Th1, Th2, Th17, Treg) using a novel developed protocol. T cell differentiation was validated by flow cytometry. Chondrocytes were mono- and co-cultured with T cell subsets and in culture supernatant cytokine and metalloproteinase levels were quantified using ELISA and multiplex assays. Compared to monocultures levels MMP-1/3/9/13 and IL-6 were elevated in all co-cultures of chondrocytes and CD4+ T cell subsets, with the highest levels in Th17 co-cultures. GM-CSF, IL-9, IL-17 were specifically elevated in Th17 co-cultures and IFN-γ in Th1 co-cultures. TNF-α production was significantly reduced only in Treg co-culture compared to monoculture approach. This study indicates that chondrocytes can interact with CD4+ T cell subsets in OA, modulating the production of metalloproteinases and cytokines to varying degrees, depending on the CD4+ T cell subset. Our findings can open new avenues in OA treatment using T cell-based or T cell subset-targeted therapies to modulate inflammatory patterns in affected OA joints.
Platelet-rich plasma (PRP) is increasingly used in orthopedics, with its regenerative potential attributed to platelet-derived cytokines and growth factors. However, variability in PRP composition hampers standardization and reproducibility, contributing to inconsistent outcomes. Since platelet counts in whole blood follow circadian rhythms, we investigated whether blood collection time affects PRP composition. Venous blood was collected from 25 healthy individuals at 8:00 a.m., 12:00 p.m., and 4:00 p.m. Whole blood was analyzed, and leukocyte-poor PRP (LP-PRP) was prepared for quantification of erythrocytes, leukocytes, and platelets. Platelets were lysed by freeze–thaw cycles, and protein levels of PDGF-BB, IGF1, HGF, IL6, and IL10 were measured via ELISA. Whole blood exhibited diurnal variation in platelet counts. In contrast, LP-PRP was consistently depleted of leukocytes and erythrocytes and showed stable platelet enrichment (PRP/whole blood ratio 2.1 ± 0.3). Protein concentrations in LP-PRP did not differ across collection times. Despite marked interindividual variability, no time-dependent differences were observed in platelet or protein composition. These results demonstrate that LP-PRP is temporally stable, independent of blood sampling time. This robustness supports flexible clinical use and contributes to efforts toward PRP standardization in therapeutic practice.
Platelet-rich plasma (PRP) has gained attention in regenerative medicine due to its bio-active proteins with tissue-healing potential. However, heterogeneity in PRP composition remains a major challenge for reproducibility and standardization. Given that body mass index (BMI) affects systemic blood parameters, we investigated whether BMI affects the cellular and molecular composition of PRP. Seventy-three participants were stratified into normal weight, overweight, and obese groups. PRP was prepared using a double-syringe system, and platelet activation was induced by freeze–thaw cycles. Whole blood and PRP cell counts were analyzed, and IL6, IGF1, HGF, and PDGF-BB levels in PRP were quantified by ELISA. Platelet enrichment and levels of IGF1, HGF, and PDGF-BB in PRP did not significantly differ between BMI groups. In contrast, IL6 concentrations were higher in normal-weight compared to overweight and obese individuals. Moreover, BMI-related associations emerged between platelet counts and PDGF-BB, and between PRP proteins and sex or caffeine intake, suggesting a more complex BMI-specific modulation of PRP composition. In conclusion, our findings support considering BMI as a relevant factor in PRP therapy. Incorporating BMI into PRP standardization strategies could improve reproducibility and support personalized regenerative approaches.